Abstract

Introduction: Doxorubicin (DOX), a widely used antineoplastic compound, is associated with testicular damage and infertility. This study was carried out to disclose the possible preventive effects of simvastatin (SIM), a lipid lowering agent with antioxidant and anti-inflammatory activities, against testicular morphometric-stereological changes due to DOX treatment in mice. Materials & methods: Male mice, five weeks old, were randomly divided into four groups of six mice each. The DOX was administered to two groups of mice in 5 equal intraperitoneal injections over a period of 4 weeks (4 mg/kg). One of these groups received 5 equal oral doses of SIM (12 mg/kg) along with DOX. A vehicle-treated control group and a SIM control group were also included. Morphometric measurement was determined using calibrated ocular micrometer. Findings: Histomorphometrical examinations revealed significant reductions in the seminiferous tubules diameters and their epithelial heights along with an increase in testicular capsule thickness and interstitial space widening in DOX-treated mice. All above-mentioned parameters recovered significantly by SIM co-administration. Discussion & conclusions: These results indicated that SIM may have a preventive role against morphometric-stereological changes caused by DOX in mouse testis.

Highlights

  • Doxorubicin (DOX), a widely used antineoplastic compound, is associated with testicular damage and infertility

  • into four groups of six mice each. The DOX was administered to two groups of mice

  • These results indicated that SIM may have a preventive role against morphometric-stereological changes caused by

Read more

Summary

Introduction

Doxorubicin (DOX), a widely used antineoplastic compound, is associated with testicular damage and infertility.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.